ERBB2 and neoplasm: Consistent with reduction in c-Src activation and p130Cas-initiated signaling, the FAK-deficient ErbB2 tumour cells exhibited a proliferative defect relative to their FAK-proficient counterparts (Figure S2a in Additional file 2).